Press Releases

Media Mentions

  • Mar 10, 2020

    Prognostic Lung Fibrosis Consortium (PROLIFIC) /Myriad RBM Collaborate on Pulmonary Fibrosis Biomarker Panel

    Celgene, a wholly owned subsidiary of Bristol-Myers Squibb Company, created a consortium called PROLIFIC (Prognostic Lung Fibrosis Consortium). Members include: Biogen, Genentech, Inc., Lung Therapeutics, Inc., OptiKira LLC, Pliant Therapeutics, Inc. and Respivant Sciences GmbH and the Pulmonary Fibrosis Foundation.

    Read the Article
    Source: Rules-Based Medicine (RBM)
  • Mar 09, 2020

    PFF Partners With Industry to Develop Individualized PF Treatment Strategies

    The Pulmonary Fibrosis Foundation (PFF) and Celgene, a subsidiary of Bristol-Myers Squibb, are leading a collaboration with the long-term goal of streamlining the development of targeted treatment strategies for idiopathic pulmonary fibrosis (IPF), and the identification of disease biomarkers.

    Read the Article
    Source: Pulmonary Fibrosis News